AstraZeneca Says Farxiga Has Been Approved By FDA To Improve Glycaemic Control In Paediatric Patients With Type-2 Diabetes Aged 10 Years And Older
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca announced that its drug Farxiga has received FDA approval to improve glycaemic control in paediatric patients with Type-2 diabetes aged 10 years and older.
June 12, 2024 | 7:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Farxiga has been approved by the FDA to improve glycaemic control in paediatric patients with Type-2 diabetes aged 10 years and older. This approval could potentially expand the market for Farxiga and boost AstraZeneca's revenues.
The FDA approval for Farxiga in a new patient demographic (paediatric Type-2 diabetes patients) is likely to expand the drug's market, potentially increasing AstraZeneca's revenues. This positive regulatory news is expected to have a favorable short-term impact on AZN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100